VIROGENICS, INC.
Biotech · Acquired
CMS121, a small-molecule oral therapeutic for Alzheimer's Disease
- Grants
- $6.8M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD | $771,449 | |
| Federal grant | Department of Health and Human Services · Phase II · Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD | $728,550 | |
| Federal grant | Department of Health and Human Services · Phase II · Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD | $977,956 | |
| Federal grant | Department of Health and Human Services · Phase II · Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD | $967,956 | |
| Federal grant | Department of Health and Human Services · Phase II · Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD | $965,711 | |
| Federal grant | Department of Health and Human Services · Phase II · Paving the Way to Phase 2 Trials of CMS121 for Alzheimer's Disease | $2,432,649 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2264 | SOTERIA SYSTEMS, INC. | — | $2.7M |
| 2265 | LineaGen, Inc | — | $38M |
| 2266 | GPER G-1 Development Group LLC | — | — |
| 2267 | VIROGENICS, INC. | — | — |
| 2268 | PRODIGY BIOTECH, INC. | — | — |
| 2269 | PranaX Corp | — | $10M |
| 2270 | Lilac Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.